Spontaneous Tumor Incidence in rasH2 Mice
暂无分享,去创建一个
[1] K. Olejniczak,et al. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009). , 2011, Regulatory toxicology and pharmacology : RTP.
[2] C L Alden,et al. A Critical Review of the Effectiveness of Rodent Pharmaceutical Carcinogenesis Testing in Predicting for Human Risk , 2011, Veterinary pathology.
[3] G. Long,et al. Alternative Mouse Models for Carcinogenicity Assessment: Industry Use and Issues with Pathology Interpretation , 2010, Toxicologic pathology.
[4] M. Pino,et al. Proliferative and Nonproliferative Lesions of the Rat and Mouse Respiratory Tract , 2009, Toxicologic pathology.
[5] Douglas C. Wolf,et al. Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions , 2009, Toxicologic pathology.
[6] X. Palazzi,et al. Use of rasH2 transgenic mice for carcinogenesis testing of medical implants. , 2009, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[7] R. Weaver,et al. N-Methyl-N-Nitrosourea (MNU): A Positive Control Chemical for p53+/− Mouse Carcinogenicity Studies , 2008, Toxicologic pathology.
[8] K. Machida,et al. Carcinogenic comparative study on rasH2 mice produced by two breeding facilities. , 2008, The Journal of toxicological sciences.
[9] Kyoko Watanabe,et al. Carcinogenic susceptibility of rasH2 mice to troglitazone , 2007, Archives of Toxicology.
[10] A. Unami,et al. The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice. , 2007, Cancer letters.
[11] K. Mitsumori,et al. A 26-Week Carcinogenicity Study of 2-Amino-3-Methylimidazo[4,5-f]Quinoline in rasH2 Mice , 2006, Toxicologic pathology.
[12] Tomoyuki Watanabe,et al. Susceptibilities of p53 Knockout and rasH2 Transgenic Mice to Urethane-Induced Lung Carcinogenesis are Inherited from their Original Strains , 2005, Toxicologic pathology.
[13] J. French,et al. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[14] K. Mitsumori. Evaluation on carcinogenicity of chemicals using transgenic mice. , 2002, Toxicology.
[15] H. Suemizu,et al. Transgene stability and features of rasH2 mice as an animal model for short‐term carcinogenicity testing , 2002, Molecular carcinogenesis.
[16] C. Alden,et al. The Tg rasH2 Mouse in Cancer Hazard Identification , 2002, Toxicologic pathology.
[17] Peter Smith,et al. Application of Genetically Altered Models as Replacement for the Lifetime Mouse Bioassay in Pharmaceutical Development , 2002, Toxicologic pathology.
[18] N. Tamaoki,et al. The rasH2 Transgenic Mouse: Nature of the Model and Mechanistic Studies on Tumorigenesis , 2001, Toxicologic pathology.
[19] M Takoaka,et al. CB6F1-rasH2 Mouse: Overview of Available Data , 2001, Toxicologic pathology.
[20] T. Nomura,et al. Pathological Features of Spontaneous and Induced Tumors in Transgenic Mice Carrying a Human Prototype c-Ha-ras Gene Used for Six-Month Carcinogenicity Studies , 1998, Toxicologic pathology.
[21] M. Katsuki,et al. Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. , 1992, Cancer research.
[22] M. Katsuki,et al. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. , 1990, Oncogene.
[23] Sue-N. Park,et al. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice , 2010, Archives of Toxicology.
[24] R. Wall,et al. Are animal models as good as we think? , 2008, Theriogenology.
[25] U. Mohr. International Classification of Rodent Tumors. The Mouse , 2001, Springer Berlin Heidelberg.